We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Some Restructuring of CDER's New Drug Office Moving Ahead
Some Restructuring of CDER's New Drug Office Moving Ahead
March 18, 2005
The FDA has delayed its timetable for restructuring the Office of New Drugs (OND), but some activities already are moving forward at the OND, including in the unit that reviews cancer products.